Answers are grounded in this paper and cite their sources.
Review highlights biomarker discovery and technological approaches for managing neuroinflammaging in aging-related brain disorders.
The progression and advancement of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), are significantly influenced by neuroinflammaging, a chronic, low-grade neuroinflammatory state linked to brain aging. This review explores the mechanistic underpinnings of neuroinflammaging, focusing on sex-specific differences in glial cell behavior, cytokine signaling, epigenetic regulation, and blood–brain barrier integrity. Advances in biomarker discovery for early detection and monitoring of aging-related neuroinflammatory processes, highlighting molecules such as interleukin (IL)-1β, tumor necrosis factor-α (TNF-α), chitinase-3-like protein 1 (YKL-40), and neurofilament light, have also been discussed. This review integrates emerging technological and engineering-based strategies from gene editing (clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)) and senolytics to microbiota-based therapeutics, organ-on-chip models, and artificial intelligence-driven predictive tools for intervention and modelling of brain senescence. It also highlights the potential of precision medicine in addressing sex-specific vulnerabilities and designing personalized therapeutic strategies by fusing biological mechanisms with translational technologies. Developing a scalable, system-level therapy that targets neuroinflammaging and promotes healthy brain aging is the goal of this interdisciplinary synthesis.
No takes yet. Share an insight, caveat, or question.
Alrouji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: